News
Pfizer beats Q2 estimates with rising oncology sales, new drug launches, and strong Seagen-driven portfolio growth.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
13h
Zacks Investment Research on MSNNovo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
Novo Nordisk (NVO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider ...
1d
Zacks.com on MSNCan Eli Lilly Keep Up as NVO Eyes First Oral Obesity Pill Approval?
The two main players in the global obesity market are Eli Lilly LLY and Novo Nordisk NVO, with their respective GLP-1 ...
Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.
19d
Zacks Investment Research on MSNNovo Nordisk (NVO) is a Top-Ranked Momentum Stock: Should You Buy?
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...
Investors should continue to retain this Zacks Rank #3 (Hold) stock in their portfolio as it appears to have significant ...
Investors and analysts say they expect Eli Lilly to report stronger quarterly sales and profit next week than Danish rival Novo Nordisk did on Tuesday, and are anxiously awaiting a full-year outlook ...
Tempus AI TEM and NVIDIA NVDA are both actively working at the intersection of AI and healthcare. Tempus AI, while advancing precision oncology through AI-driven diagnostics and a landmark $200 ...
Shares of Hims & Hers tumbled 12% in after-hours trading Monday after the company's second-quarter revenue missed Wall Street ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results